Evotec remains a speculative 'buy' with a maintained share price target, reflecting deep undervaluation despite a >50% market cap decline. EVO's biologics segment shows positive EBITDA and 11% growth, ...
HAMBURG, DE / ACCESS Newswire / November 5, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ: EVO) today announced its business ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results